By
AmyT on
January 3, 2011
Happy New Year, everyone! I’ve been mostly off-line this past week, attempting to enjoy the “break” while cleaning and sorting out our fresh-from-construction home. But even in that daze, I couldn’t help noticing all the fuss about MannKind’s Afrezza, which was supposed to be ruled upon by the FDA on Dec. 29.
The FDA has requested an additional four weeks to make a decision on this new inhalable insulin, after having postponed the decision by…
Read more »
By
AmyT on
December 22, 2010
While blogs are hugely popular for sharing our day-to-day trials of living with diabetes, there’s also been a new crop of self-published books about the Big D making their way online in virtual stores, including Amazon. A recent title is Tales in the Insulin Vial, by Steve Beriault, a 58-year-old type 1 living in Canada.
Steve’s book is more of a collection of stories than a straightforward memoir. Some of those stories capture a true…
Read more »
By
AmyT on
November 3, 2010
Why is affordable generic insulin not available to patients in the US? Mainly because the big manufacturers have a stronghold on the patents for this complicated “biologic” drug. But now it seems Big Pharma itself may be presenting a nice alternative.
What I’m talking about is Pfizer’s new attempt to enter the injectable insulin market (less risky than their Exubera flop!) Pfizer and Biocon, a biopharmaceutical company in India, recently announced a multimillion dollar partnership…
Read more »
By
AmyT on
September 23, 2010
Earlier this week, Novo Nordisk released results of a sweeping new survey about how patients — both type 1 and type 2 — struggle with insulin therapy, and what doctors accredit that to.
Entitled the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM), the survey was conducted among almost 3,000 physicians and patients in eight countries “with the objective to learn what they perceive to be the biggest functional and emotional unfulfilled needs…
Read more »
By
AmyT on
August 23, 2010
My Spring post on the new injectable type 2 diabetes drug Victoza is in the running for one of the most-commented-ever blog posts here at the ‘Mine. Over 100 people now taking the medication have chimed in.
Victoza, for the unfamiliar, is a new once-daily form of the new-generation GLP-1 drugs that stimulate pancreas cells to release insulin in people with type 2 diabetes. It’s a head-to-head competitor with the injectable drug Byetta, and both…
Read more »
